Pimda.eu

Results from PIMDA

pimdawp — Thu, 03 Oct 2013 13:37:26 +0000

A publication is in development for the PIMDA study

Poster on PIMDA presented at ECCMID in Barcelona, May 2014

pimdawp — Fri, 01 Mar 2013 11:31:37 +0000

Download the ePoster

PIMDA study completed

pimdawp — Mon, 10 Dec 2012 11:48:07 +0000

This study has now been completed and the results are being analysed

Screening Logs

pimdawp — Mon, 19 Nov 2012 12:30:39 +0000

Please remember to send your screening logs to admin@pimda.eu, covering the full 6 month period from 6 June – 4 December. Please list ALL patients admitted to hospital who were given chemotherapy either for AML/MDS or to prepare for a transplant during the period. Blank forms can be downloaded from Study Documentation.

Enrolment Period Extended to 26 weeks

pimdawp — Mon, 19 Nov 2012 12:29:16 +0000

Please continue to enrol all eligible patients who have their first dose of chemotherapy right up to midnight on 4th December 2012. The database will remain open until Monday December 24th to allow these patients to be entered. However only those whose first dose of chemotherapy preceded December 5th will be accepted in the analysis as being enrolled.

Enrolment Period Extended

pimdawp — Wed, 22 Aug 2012 17:41:04 +0000

The study opened for patient enrolment on 6 June 2012, and patients will continue to be enrolled until the target of 1,000 eligible patients is reached (to a maximum of 24 weeks, i.e. up to 21 November 2012). After enrolment patients will be observed for up to 26 weeks.

Examples:

Patient does not develop IMD:
Enrolled, observed for 12 weeks.
Survival assessed at 26 weeks after enrolment.

Patient does develop IMD:
Enrolled, observed until IMD is diagnosed.
Followed for 12 weeks from start of antifungal therapy.
Survival assessed at 26 weeks after enrolment.

Clarifications on data entry

pimdawp — Thu, 28 Jun 2012 11:10:32 +0000

Clarifications on patient enrolment and data entry have been added to the HELP section. Please review these, as they may address some of your own questions.